ctDNA Testing May Better Predict Breast Cancer Recurrence Than Current Standard
A study reports that post-treatment circulating tumor DNA levels may better predict recurrence in HER2-positive breast cancer patients than current pCR measures.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
